Dfe Pharma
Dfe Pharma, headquartered in Germany, is a leading provider of excipients and pharmaceutical solutions, specialising in the development and manufacturing of high-quality products for the global pharmaceutical industry. Founded in 2015, the company has quickly established itself as a key player in the market, with a strong presence in Europe, North America, and Asia. Dfe Pharma's core offerings include a diverse range of excipients, such as binders, fillers, and disintegrants, which are essential for the formulation of solid dosage forms. What sets Dfe Pharma apart is its commitment to innovation and quality, ensuring that their products meet the stringent requirements of the pharmaceutical sector. With a focus on customer collaboration and tailored solutions, Dfe Pharma continues to enhance its market position, contributing to the success of its partners in the ever-evolving pharmaceutical landscape.
DitchCarbon Score
How does Dfe Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Dfe Pharma's score of 42 is higher than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Dfe Pharma's reported carbon emissions
In 2024, DFE Pharma reported significant carbon emissions, with total Scope 3 emissions amounting to approximately 815,000,000 kg CO2e. This marks a decrease from 2023, where Scope 3 emissions were about 917,000,000 kg CO2e, and from 2022, which recorded approximately 931,000,000 kg CO2e. The company has set ambitious climate commitments, aiming for 100% carbon neutrality in Scope 1 and 2 emissions by 2030, starting from a 2023 baseline. DFE Pharma has established specific reduction targets under the Science Based Targets initiative (SBTi). The company aims to reduce absolute Scope 1 and 2 greenhouse gas emissions by 42% by 2030, using 2021 as the base year. Additionally, it targets a 25% reduction in Scope 3 emissions, which encompass purchased goods and services, upstream transportation, and end-of-life treatment of sold products, also by 2030. Furthermore, DFE Pharma is committed to reducing Scope 3 FLAG emissions by 30.3% within the same timeframe and has pledged to achieve no deforestation across its primary deforestation-linked commodities by December 31, 2025. These initiatives reflect DFE Pharma's commitment to addressing climate change and reducing its overall carbon footprint in the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 6,566,000 | - | - | - | - |
| Scope 2 | 7,916,000 | - | - | - | - |
| Scope 3 | 989,802,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Dfe Pharma is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
